A5101439536- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Chronic Lymphocytic Leukemia Research
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Lymphoma Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- MRI in cancer diagnosis
- Neuroendocrine Tumor Research Advances
- Acute Myeloid Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Radiomics and Machine Learning in Medical Imaging
- Statistical Methods in Clinical Trials
- Ferroptosis and cancer prognosis
- Meta-analysis and systematic reviews
- Cancer Immunotherapy and Biomarkers
- Acute Lymphoblastic Leukemia research
- Lung Cancer Research Studies
- Hormonal and reproductive studies
- Radiopharmaceutical Chemistry and Applications
- Economic and Financial Impacts of Cancer
- Cancer-related gene regulation
- Angiogenesis and VEGF in Cancer
- Advanced Causal Inference Techniques
Dana-Farber Cancer Institute
2016-2025
ECOG-ACRIN Cancer Research Group
2022-2024
Boston University
2024
Harvard University
2013-2023
Princess Margaret Cancer Centre
2014
University Health Network
2014
University of Toronto
2014
Center for Cancer Research
2013-2014
Massachusetts General Hospital
2013-2014
Hunter College
2014
Abstract Herein, we present the long-term follow-up of randomized E1912 trial comparing efficacy ibrutinib–rituximab (IR) therapy to fludarabine, cyclophosphamide, and rituximab (FCR) describe tolerability continuous ibrutinib. The enrolled 529 treatment-naïve patients aged ≤70 years with chronic lymphocytic leukemia (CLL). Patients were randomly assigned (2:1 ratio) receive IR or 6 cycles FCR. With a median 5.8 years, progression-free survival (PFS) is superior for (hazard ratio [HR], 0.37;...
Efavirenz is a potent and selective nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT). Nucleotide sequence analyses the protease RT genes (coding region for amino acids to 229) multiple cloned HIV-1 genomes from found in plasma patients phase II clinical studies efavirenz combination therapy were undertaken order identify spectrum mutations plasma-borne associated with virological treatment failure. A K103N substitution was gene mutation most...
This article introduces a manually curated data collection for gene expression meta-analysis of patients with ovarian cancer and software reproducible preparation similar databases. resource provides uniformly prepared microarray 2970 from 23 studies documented clinical metadata. It allows users to efficiently identify patient subgroups interest analysis perform immediately without the challenges posed by harmonizing heterogeneous technologies, study designs, processing methods formats. We...
Short-read data from next-generation sequencing technologies are now being generated across a range of research projects. The fidelity this can be affected by several factors and it is important to have simple reliable approaches for monitoring at the level individual experiments.We developed fast, scalable accurate approach estimating error rates in short reads, which has added advantage not requiring reference genome. We build on fundamental observation that there linear relationship...
Bruton tyrosine kinase inhibitors (BTKis) that target B-cell receptor signaling have led to a paradigm shift in chronic lymphocytic leukemia (CLL) treatment. BTKis been shown reduce abnormally high CLL-associated T-cell counts and the expression of immune checkpoint receptors concomitantly with tumor reduction. However, impact BTKi therapy on function has not fully characterized. Here, we performed longitudinal immunophenotypic functional analysis pretreatment on-treatment (6 12 months)...
<p>Supplementary Figure 1: Progression Free and Overall Survival in the Eligible Treated Population (n=38) Kaplan Meier plots for progression free (A) overall (B) survival eligible treated population (n=38)</p>
<div>AbstractPurpose:<p>Amplification of cyclin-dependent kinase 4 (CDK4) and CDK6 is a feature variety malignancies, preclinical evidence suggests that inhibition CDK4/6 plausible treatment strategy in these tumors. Subprotocol Z1C the NCI-Molecular Analysis for Therapy Choice trial was designed to evaluate inhibitor palbociclib CDK4- or CDK6-amplified tumors.</p>Patients Methods:<p>Patients had solid malignancy lymphoma with progression on at least one systemic...
<p>Receiver operating curve demonstrating relationship between tumor mutational burden and clinical benefit</p>
<p>Mutations across genes by type and/or frequency</p>
<p>Differences in infiltrating immune cell populations as determined by multiplex immunofluorescence among subjects with and without clinical benefit</p>
<p>Gene mutation profile in the cohort with corresponding clinical benefit status, MSI score, best confirmed response and TMB score</p>
<p>Mutational comparisons with clinical benefit</p>
<div>AbstractPurpose:<p>Mismatch repair–deficient (dMMR) tumors have demonstrated favorable responses to immune checkpoint inhibition targeting PD-1. However, more in-depth identification of predictors response could further refine patient selection for immunotherapy treatment.</p>Patients and Methods:<p>We undertook integrated evaluation performed on samples collected from 28 42 patients enrolled the NCI–Molecular Analysis Therapy Choice arm Z1D trial that evaluated...
<p>Comparisons of clinical outcomes, MSIsensor-pro scores, and tumor mutational burden (TMB)</p>
<p>Subject MSI and MANTIS score correlation</p>